Organization (Academic)
University of Rhode Island
ClinicalTrials.gov lists University of Rhode Island as lead sponsor of 34 trials. It has 7 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo The University of Rhode Island, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Rhode Island: 34 lead-sponsored trials and 1 legal-entity registration.
Disease areas (60)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 9 |
| Anemia | 4 |
| Alcoholism | 3 |
| Alzheimer Disease | 3 |
| Cognitive Dysfunction | 3 |
Showing 5 of 60 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Colesevelam | Hypercholesterolemia | Phase 2 | 1 |
| Colesevelam | Hyperlipidemias | Phase 2 | 1 |
| Colesevelam | Dyslipidemias | Phase 2 | 1 |
| Dabigatran | Cognitive Dysfunction | Phase 1 | 1 |
| TREATMENT | Inflammation | Not reported | 1 |
Showing 5 of 7 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Lisdexamfetamine Dimesylate | 1 |
| Colesevelam | 1 |
| Dabigatran | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 25% hit target (n=12) | 50% on time (n=12) |
Journals published in (56)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Appetite | 3 |
| Journal of interpersonal violence | 3 |
| Journal of perinatology : official journal of the California Perinatal Association | 3 |
| Pediatrics | 3 |
| The Journal of pediatrics | 3 |
Showing 5 of 56 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7 | 0 | 2018-12-18 |
Financing and grant events (198)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-23 | NIH grant | 171,211 | Reporter |
| 2025-09-15 | NIH grant | 723,736 | Reporter |
| 2025-08-30 | NIH grant | 4,119,364 | Reporter |
| 2025-08-27 | NIH grant | 184,900 | Reporter |
| 2025-08-21 | NIH grant | 902,083 | Reporter |
Showing 5 of 198 events.
Organization relationships (15)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Brown University | Co sponsors trial with | 3 |
| Government of the United States of America | Co sponsors trial with | 2 |
| University of California System | Co sponsors trial with | 2 |
| BayCare Health System | Co sponsors trial with | 1 |
| Washington University in St. Louis | Co sponsors trial with | 1 |
Showing 5 of 15 relationships.
Latest dated events (264)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-15 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 264 events.
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACAT1 | Trial collaborator | Named in trial inclusion criteria |
| ACAT1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| APOE | Trial collaborator | Named in trial inclusion criteria |
| APOE | Trial sponsor | Named in trial inclusion criteria |
| CDR1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 28 evidence rows.
Biomarkers this organization publishes on (142)
Shown in this order: most publications first.
Showing 5 of 142 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.